Oct. 21, 2024
| Today’s news and insights for biopharma leaders
Q&A
Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a "huge value disconnect" its leaders are trying to bridge.
|
Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.
|
The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.
|
Over the past several years, a number of biotech companies have made strides in constructing small molecule drugs to target RNA. Explore the latest developments in these research efforts in
|
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
|
UPDATED
Septerna set terms for an IPO that would fund a pipeline of drugs it’s evaluating against a variety of conditions, from hypoparathyroidism to obesity.
|
|
Single-cell RNA sequencing is underutilized in pharma, but could it hold the key to more effective drug development? Explore the barriers and future potential in this must-see webinar.
|
|
From Our Library
Playbook
Custom content for KIMTECH™
|
Playbook
Custom content for Avant Healthcare
|
Playbook
Custom content for Fortrea
|
| 
